Rapid Theraptic Scince Lab (RTSL) Stock Price, News & Analysis
Company Description
Rapid Theraptic Scince Lab (OTC Link: RTSL) is classified in the shell companies industry within the Financial Services sector and carries a market capitalization of $57.0K.
RTSL has declined 98.7% over the past year. Shares last traded at $0.0001.
For FY2022, Rapid Theraptic Scince Lab reported revenue of $0 with net income of -$1.8M.
This page collects what Stock Titan holds for RTSL, including price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Rapid Theraptic Scince Lab (RTSL) stock last closed at $0.0001. Over the past 12 months, the stock has lost 98.7%. At a market capitalization of $57.0K, RTSL is classified as a micro-cap stock with approximately 19.0M shares outstanding.
Latest News
Rapid Theraptic Scince Lab has 10 recent news articles. Of the recent coverage, 3 articles coincided with positive price movement and 4 with negative movement. Key topics include conferences, stock split. View all RTSL news →
SEC Filings
Financial Highlights
net income was -$1.8M. The company generated -$1.2M in operating cash flow. With a current ratio of 0.05, short-term liquidity bears monitoring.
Upcoming Events
Short Interest History
Days to Cover History
RTSL Company Profile & Sector Positioning
Rapid Theraptic Scince Lab (RTSL) operates in the Shell Companies industry within the broader Financial Services sector and is listed on the OTC Link.
Investors comparing RTSL often look at related companies in the same sector, including Better For You Wellness Inc (BFYW), DRAZCANNA INC (DZCA), Monkey Rock Group Inc (MKRO), Transatlantic (TACI), and Calithera Biosciences Inc (CALA). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate RTSL's relative position within its industry.